Patients

Despite the answers we are still seeking, huge progress has been made since the initial discovery of anti-cancer drugs – and all in a relatively short space of time. Indeed, the pace of advancement has never been more rapid than it is today.

Australia’s economy is in transition. The nation is actively trying to set course for an economy where the relative GDP footprint earned from being the world’s quarry is smaller, replaced all manner of services, knowledge and experiences; mostly exported into emerging Asian countries. We are plotting a plan to be less brawn, more brains. Less soil, more skills.

The strong growth potential of emerging economies, such as those within the Association of Southeast Asian Nations (ASEAN), continues to attract attention from global businesses.

Cancer patients who otherwise would shy away from visiting the gym because of an altered appearance and lack of confidence are thriving as a result of an innovative 12-week exercise program.

Non-alcoholic Steatohepatitis, or NASH, is a liver disease characterized by rising prevalence, low diagnosis and a lack of therapies approved for treatment. All of these factors combine to make NASH a priority for the healthcare industry – and, potentially, a multi-billion-dollar market. Accordingly, the race is now on among several pharma companies to develop the first effective pharmacotherapy to treat NASH.

This study looks at awareness and perceptions of Pneumonia among the 50+ population in nine European markets.

In light of the most recent news regarding the spread of the Zika virus, Ipsos conducted a poll to gauge the level of concern about the virus among citizens of 27 countries around the world.

As an increasing number of drugs gain approval for patients whose cancers have certain molecular characteristics, the promise of truly personalised medicine is edging closer towards reality.

Pulmonary Arterial Hypertension (PAH) is a life-threatening, degenerative disease that severely compromises the function of both the pulmonary (lung) and cardiovascular (heart) systems. Despite current treatment options in PAH offering improvements in symptom control and quality of life factors, there continue to be significant challenges that compromise the effective management of this progressive and debilitating condition.